Co-Crystalization and In Vitro Biological Characterization of 5-Aryl-4-(5-Substituted-2-4-Dihydroxyphenyl)-1,2,3-Thiadiazole Hsp90 Inhibitors

• Swee Y. Sharp,

  Affiliation Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom

  ⨯
• S. Mark Roe,

  Affiliation Biochemistry and Molecular Biology, Chichester 2, University of Sussex, Brighton, Falmer, United Kingdom

  ⨯
• Egidijus Kazlauskas,

  Affiliation Laboratory of Biothermodynamics and Drug Design, Institute of Biotechnology, Vilnius University, Vilnius, Lithuania

  ⨯
• Inga Čikotienė,

  Affiliation Department of Organic Chemistry, Faculty of Chemistry, Vilnius University, Vilnius, Lithuania

  ⨯
• Paul Workman,

  Affiliation Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom

  ⨯
• Daumantas Matulis,

  Affiliation Laboratory of Biothermodynamics and Drug Design, Institute of Biotechnology, Vilnius University, Vilnius, Lithuania

  ⨯
• Chrisostomos Prodromou

  * E-mail: chris.prodromou@sussex.ac.uk

  Affiliation Genome Damage and Stability Centre, University of Sussex, Brighton, Falmer, United Kingdom

  ⨯